Business Context and Reporting Period
Company: Ligand Pharmaceuticals Incorporated (LGND)
Filing Type: Form 8-K (Current Report)
Date of Report: February 26, 2026
Reporting Period: The filing announces financial results for the three and twelve months ended December 31, 2025.
Key Financial Metrics
The provided text is a cover sheet for a Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) containing the actual results. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit (Net Income/Loss)
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
The filing text does not disclose specific material changes versus prior periods. It serves only to notify the market that results for the period ended December 31, 2025, have been issued.
Guidance, Outlook, and Risks
No guidance, outlook, management commentary, risks, contingencies, or unusual items are detailed in the provided text. The document states that the information in the accompanying press release is furnished but not "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 26, 2026) for actual revenue, earnings, and cash flow figures.
- Verify the specific performance of the three and twelve months ended December 31, 2025, against prior year guidance.
- Check for any forward-looking statements or updated guidance included in the referenced press release.
- Confirm the status of the company's liquidity and debt obligations as detailed in the full financial report.